BACKGROUND: The study's objective was to assess the predictive factors of anemia induced by chemotherapy in early breast cancer patients. PATIENTS AND METHODS: Patients treated by adjuvant or neo-adjuvant anthracyclin-based regimens with or without taxanes between 1998 and 2006 in a French university hospital were studied. Chemotherapy included. Anemia was defined as a hemoglobin (Hb) concentration lower than 12 g/dL. Multivariate analysis by logistic regression was used to search for baseline risk factors linked to the occurrence of anemia. RESULTS: Among 378 patients, anemia was observed in 64% of cases. The occurrence of anemia was significantly related to 6 risk factors: exposure to taxanes (HR 11.5, 95% CI, 2.5-52.6), high dose of anthracyclin (epirubicin 100 mg/m²)(HR 4.3; 95% CI, 2.8-8), Hb at baseline < 13.5 g/d (HR 4.3; 95% CI, 2.6-7.1), mastectomy (HR 2.5; 95% CI, 1.4-3.3), age >60 (HR 2.5; 95% CI, 1.4-5) years old (HR 2.5; 95% CI, 1.4-5) and Body Mass Index (BMI) ≤ 25 kg/m² (HR 1.7; 95% CI, 1.0-2.8). CONCLUSION: Taking into account the following factors: type of chemotherapy, BMI, age, Hb at baseline should allow a better identification of patients at risk of anemia.
BACKGROUND: The study's objective was to assess the predictive factors of anemia induced by chemotherapy in early breast cancerpatients. PATIENTS AND METHODS: Patients treated by adjuvant or neo-adjuvant anthracyclin-based regimens with or without taxanes between 1998 and 2006 in a French university hospital were studied. Chemotherapy included. Anemia was defined as a hemoglobin (Hb) concentration lower than 12 g/dL. Multivariate analysis by logistic regression was used to search for baseline risk factors linked to the occurrence of anemia. RESULTS: Among 378 patients, anemia was observed in 64% of cases. The occurrence of anemia was significantly related to 6 risk factors: exposure to taxanes (HR 11.5, 95% CI, 2.5-52.6), high dose of anthracyclin (epirubicin 100 mg/m²)(HR 4.3; 95% CI, 2.8-8), Hb at baseline < 13.5 g/d (HR 4.3; 95% CI, 2.6-7.1), mastectomy (HR 2.5; 95% CI, 1.4-3.3), age >60 (HR 2.5; 95% CI, 1.4-5) years old (HR 2.5; 95% CI, 1.4-5) and Body Mass Index (BMI) ≤ 25 kg/m² (HR 1.7; 95% CI, 1.0-2.8). CONCLUSION: Taking into account the following factors: type of chemotherapy, BMI, age, Hb at baseline should allow a better identification of patients at risk of anemia.
Authors: Xavier Pivot; Laura Mansi; Loic Chaigneau; Philippe Montcuquet; Antoine Thiery-Vuillemin; Fernando Bazan; Erion Dobi; Jean L Sautiere; Frederic Rigenbach; Marie P Algros; Steve Butler; Farid Jamshidian; Phillip Febbo; Christer Svedman; Sophie Paget-Bailly; Franck Bonnetain; Christian Villanueva Journal: Oncologist Date: 2015-03-20
Authors: Parth Sharma; Josh Thomas Georgy; Anand George Andrews; Ajoy Oommen John; Anjana Joel; Raju Titus Chacko; Prasanna Samuel Premkumar; Ashish Singh Journal: Support Care Cancer Date: 2022-03-21 Impact factor: 3.359
Authors: Fares M S Muthanna; Mahmathi Karuppannan; Egbal Abdulrahman; Suriyon Uitrakul; Bassam Abdul Hassan Rasool; Ali Haider Mohammed Journal: Adv Pharmacol Pharm Sci Date: 2022-04-14